Arca
Skip to content
Tools
Tools

Label Changes: Lenvima (lenvatinib mesylate)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Lenvima label DailyMed has published, from Eisai Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 42
  • Sections changed, version 81 to 82: 6

What changed from version 81 to version 82

Oct 8, 2026 to Oct 22, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Dosage and administrationChanged ยท 1 word added, 1 removed
  2. Warnings and precautionsChanged ยท 6 words added
  3. Adverse reactionsChanged ยท 3 words added
  4. Clinical studiesChanged ยท 4 words added, 4 removed
  5. Patient counseling informationChanged ยท 1 word added, 2 removed
  6. Patient informationChanged ยท 3 words added, 4 removed

Dosage and administration

Changed1 word added, 1 removed
32 unchanged lines
Fistula Formation [see Warnings and Precautions ( 5.8 )] | Grade 3 or 4 | Permanently discontinue.
QTc Prolongation [see Warnings and Precautions ( 5.9 )] | Greater than 500 ms or greater than 60 ms increase from baseline | Withhold until QTc improves to less than or equal to 480 ms or baseline. Resume at a reduced dose. Permanently discontinue for persistent QTc greater than 500 ms or for ventricular arrythmiaarrhythmia
Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions ( 5.11 )] | Any Grade | Withhold until fully resolved. Resume at a reduced dose or discontinue depending on severity and persistence of neurologic symptoms.
42 unchanged lines

Warnings and precautions

Changed6 words added
20 unchanged lines
5.5 Renal Failure or Impairment
Serious adverse reactions including fatal renal failure or renal impairment, or thrombotic microangiopathy, can occur with LENVIMA. Renal impairment occurred in 14% of patients receiving LENVIMA in SELECT (DTC) and in 7% of patients receiving LENVIMA in REFLECT (HCC). Grade 3 to 5 renal failure or impairment occurred in 3% (DTC) and 2% (HCC) of patients, including 1 fatality in each study.
In Study 205 (RCC), renal impairment or renal failure occurred in 18% of patients receiving LENVIMA with everolimus, including Grade 3 in 10% of patients [see Adverse Reactions ( 6.1 )].
39 unchanged lines

Adverse reactions

Changed3 words added
135 unchanged lines
Laboratory Abnormality a | LENVIMA 20 mg in combination with Pembrolizumab 200 mg | Sunitinib 50 mg
| All Grades % b | Grades 3-4 % b | All Grades % b | Grade s 3-4 % b
Chemistry
33 unchanged lines
Dosage interruptions of LENVIMA due to an adverse reaction occurred in 72% of patients. Adverse reactions which required dosage interruption in >3% of patients included fatigue (15%), hypertension (14%), diarrhea (13%), nausea (10%), vomiting (10%), anemia (8%), proteinuria (7%), decreased appetite (6%), COVID-19 (5%), musculoskeletal pain (4.3%), abdominal pain (4.3%), rash (4.3%), pneumonia (3.5%), stomatitis (3.5%), and hemorrhage (3.2%).
Dose reductions of LENVIMA due to an adverse reaction occurred in 67% of patients. Adverse reactions which required dose reductions in >2% included fatigue (20%), diarrhea (13%), hypertension (12%), proteinuria (9%), decreased appetite (8%), nausea (6%), rash (6%), vomiting (4.1%), anemia (3.5%), decreased weight (3.5%), abdominal pain (3%), increased ALT (2.7%), stomatitis (2.7%), musculoskeletal pain (2.4%), and hypothyroidism (2.2%).
The most common (โ‰ฅ25%) adverse reactions that occurred in patients who received LENVIMA in combination with belzutifan were anemia, fatigue, hypertension, musculoskeletal pain, diarrhea, nausea, hypothyroidism, decreased appetite, proteinuria, rash, vomiting, decreased weight, constipation, abdominal pain, and stomatitis.
37 unchanged lines
Hypoxia | 16 | 12 | 0 | 0
a Includes other related terms
Clinically relevant adverse reactions occurring in <15% of patients who received LENVIMA in combination with belzutifan included COVID-19 (14%), dysphonia (14%), dysgeusia (14%), urinary tract infection (14%), pruritus (12%), pyrexia (11%), and arrhythmia (9%).
20 unchanged lines
Increased calcium | 20 | 0.3 | 11 | 0.5
a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LENVIMA + belzutifan (range: 319 to 368 patients), and cabozantinib (range: 320 to 371 patients).
Previously T reated Renal Cell Carcinoma in Combination with Everolimus (Study 205)
214 unchanged lines

Clinical studies

Changed4 words added, 4 removed
134 unchanged lines
Tumor assessments were based on RECIST v1.1 criteria for progression but only confirmed responses are included for ORR. Data cutoff date = 13 Jun 2014 CI = confidence interval a Point estimates are based on Kaplan-Meier method and 95% CIs are based on the Greenwood formula using log-log transformation. b Hazard ratio is based on a stratified Cox regression model including treatment as a covariate factor and hemoglobin and corrected serum calcium as strata. c Data cutoff date = 31 Jul 2015
Figure 5 : Kaplan-Meier Curves for Progression-Free Survival in Study 2 05
in Study 2 05
Figure 6 : Kaplan-Meier Curves for Overall Survival in Study 2 05
66 unchanged lines

Patient counseling information

Changed1 word added, 2 removed
2 unchanged lines
Hypertension
Advise patients to undergo regular blood pressure monitoring and to contact their health carehealthcare provider if blood pressure is elevated [see Warnings and Precautions ( 5.1 )] .
Cardiac Dysfunction
35 unchanged lines

Patient information

Changed3 words added, 4 removed
7 unchanged lines
severe chest pain or pressure pain in your arms, back, neck or jaw shortness of breath numbness or weakness on one side of your body | trouble talking sudden severe headache sudden vision changes
Liver problems. LENVIMA may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with LENVIMA. Tell your healthcare provider right away if you develop any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice) dark or tea colored urine light-colored stools (bowel movements) nausea or vomiting pain in ouryour upper right stomach area (abdomen) feeling drowsy, confused, or losing consciousness Kidney problems. Kidney failure, which can lead to death, has happened with LENVIMA treatment. Your healthcare provider should do regular blood tests to check your kidneys. Tell your health carehealthcare provider if you develop any signs and symptoms of kidney problem:
changes in the amount or color of your urine blood in your urine | swelling in your legs or ankles loss of appetite
Increased protein in your urine (proteinuria). Proteinuria is a common side effect of LENVIMA and can be serious. Your healthcare provider should check your urine for protein before and during treatment with LENVIMA. Diarrhea. Diarrhea is a common side effect of LENVIMA and can be serious. If you get diarrhea, ask your healthcare provider about medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room if you are unable to drink enough liquids and your diarrhea cannot be controlled. An opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula). Get emergency medical help right away if you develop severe stomach area (abdomen) pain. Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can cause you to faint and may be life threatening. Your healthcare provider will do blood tests before and during your treatment with LENVIMA to check the salts (electrolytes) in your blood, including the levels of potassium, magnesium, and calcium, and may check the electrical activity of your heart with an electrocardiogram (ECG). Low levels of blood calcium (hypocalcemia). Your healthcare provider will check your blood calcium levels during treatment with LENVIMA and may tell you to take a calcium supplement if your calcium levels are low. A condition called Reversible Posterior Leukoencephalopathy Syndrome (RPLS). Tell your healthcare provider right away if you get any of the following new or worsening symptoms:
severe headache seizures weakness | confusion change in visonvision
Bleeding. LENVIMA can cause serious bleeding problems that may lead to death. Tell your healthcare provider right away if you develop any signs or symptoms of bleeding during treatment with LENVIMA, including:
18 unchanged lines

Unchanged: Indications and usage, Dosage forms and strengths, Contraindications, Drug interactions, Use in specific populations, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, How supplied, Package label.

Every version

42 versions of set f4bedd21-efde-44c6-9d9c-b48b78d7ed1e, newest first.
VersionPublished on DailyMedCompareSPL file
82Oct 22, 2026Shown belowDownload .zip
81Oct 8, 2026With version 80Download .zip
80Jun 30, 2026With version 78Download .zip
78Jun 6, 2025With version 77Download .zip
77Feb 10, 2025With version 76Download .zip
76Nov 27, 2024With version 73Download .zip
73Jun 19, 2024With version 69Download .zip
69Apr 15, 2024With version 67Download .zip
67Oct 27, 2023With version 64Download .zip
64Mar 14, 2023With version 60Download .zip
60Nov 17, 2022With version 58Download .zip
58Aug 16, 2022With version 56Download .zip
56Jun 2, 2022With version 52Download .zip
52Jan 10, 2022With version 51Download .zip
51Dec 24, 2021With version 50Download .zip
50Dec 1, 2021With version 49Download .zip
49Aug 19, 2021With version 48Download .zip
48Aug 2, 2021With version 47Download .zip
47Mar 5, 2021With version 42Download .zip
42Dec 22, 2020With version 41Download .zip
41Nov 16, 2020With version 40Download .zip
40Sep 16, 2020With version 38Download .zip
38Jul 6, 2020With version 35Download .zip
35Mar 12, 2020With version 34Download .zip
34Feb 25, 2020With version 32Download .zip
32Nov 12, 2019With version 30Download .zip
30Sep 24, 2019With version 26Download .zip
26Dec 13, 2018With version 25Download .zip
25Aug 22, 2018With version 23Download .zip
23Jun 21, 2018With version 22Download .zip
22Jun 14, 2018With version 20Download .zip
20Apr 4, 2018With version 19Download .zip
19Mar 30, 2018With version 16Download .zip
16Aug 8, 2017With version 14Download .zip
14Mar 17, 2017With version 13Download .zip
13Oct 31, 2016With version 12Download .zip
12Aug 24, 2016With version 10Download .zip
10May 19, 2016With version 9Download .zip
9May 18, 2016With version 8Download .zip
8Apr 29, 2016With version 7Download .zip
7Feb 18, 2016With version 4Download .zip
4Feb 26, 2015First versionDownload .zip

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.